United States · Series D startup
Funding summaryUpdated 26 Oct 2026
$333Mraised across 7 rounds since 2008, from 7 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
No investor was named in the report.
From a historical funding recordSEC filing: $106M sold, first sale Mar 2015
No investor was named in the report.
From a historical funding recordSEC filing: $106M sold, first sale Mar 2015
Reported by fiercebiotech.comSEC filing: $13M sold, first sale Apr 2013
No investor was named in the report.
Reported by fiercebiotech.comSEC filing: $13M sold, first sale Apr 2013
Reported by sec.govSEC filing: $55M sold, first sale Mar 2010
Reported by sec.govSEC filing: $27M sold, first sale Jan 2008
From a historical funding record
From NGM Biopharmaceuticals's own website and the SEC filings it signed: 5 on the team.
On the board, as filediDavid V. GoeddelDavid V. SchnellMark V. LeschlyMcHenry T. TichenorPeter V. Svennilson
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Prospect Venture Partners
Rho Capital Partners
The Column GroupTichenor Ventures
Topspin Partners
Rho VenturesSolon Mack CapitalMissing a round, or an investor who was in one? Tell us.
NGM Biopharmaceuticals's investors include Prospect Venture Partners, Rho Capital Partners, The Column Group, Tichenor Ventures and Topspin Partners, and 2 more on record.
NGM Biopharmaceuticals has raised $333M across 7 rounds since 2008.
NGM Biopharmaceuticals's most recent round was a Series D of $58M in Mar 2015.
NGM Biopharmaceuticals's largest round on record is $106M (Series E), in Mar 2015.
NGM Biopharmaceuticals's first round on record, in Feb 2008, was backed by Rho Capital Partners, Prospect Venture Partners and The Column Group.
NGM Biopharmaceuticals's latest named round is a Series D, in Mar 2015.
NGM Biopharmaceuticals is based in the United States.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
